A large retrospective cohort of KRAS-mutant NSCLC patients receiving immune checkpoint inhibitors (ICIs) has been studied: KRAS-mutant lung adenocarcinomas harboring LKB1 mutations obtained inferior response rate, shorter progression free survival (PFS) and OS to PD-1 and/or CTLA-4 blockade, compared to KRAS-mutant lung adenocarcinoma without co-mutations and to those with TP53 co-mutations. The gene discussed is TP53; the disease is lung adenocarcinoma.